ChartRow logo
Data provided bySource: Twelve Data
MEDP
$653.09+0.75%
as of close, Nov 17, 2026
☾ AH $653.09 +0.75%
PeersILMNNTRACRLRVTYIQVICLR
Share this page

MEDP — Medpace Holdings Inc. price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
Data provided bySource: Twelve Data
What would $1,000 invested in MEDP be worth today? →
MEDP returns: By year · By month · By week · Trailing

Price data

Price
$653.09
YTD price return
+16.28%
YTD total return
+16.28%
Market cap
18.3B
Enterprise value
17.7B
Shares outstanding
28M
52W low
$373.00
52W high
$693.97
From 52W high
-5.89%
From 52W low
+75.09%
52W range
87%$373–$694
Beta
1.14

Volume

Rel volume
0.62×
30D volume
282.8K
30D $ vol
183.2M

Insider trading

Insider net 1W
none
Insider net 1M
−$14.4M
Insider net 3M
−$174.9M
Insider net 1Y
−$244.7M

Form 4 transactions by trade date, as filed; latest on file 2026-10-29.

Fundamentals

Sales (ttm)
2.8B
Sales/share
$101.47
EPS (ttm)
$18.03
FCF (ttm)
667.6M
FCF/share
$23.87
Book value/share
$20.91
Net margin
18.24%
ROE
88.53%
ROA
22.49%
Current ratio
0.83

Growth (CAGR, ttm) · 10Y

Sales
+20.37%+16.79%+21.02%+21.61%
Net income
+19.60%+23.75%+23.17%+59.48%
FCF
-1.35%+20.90%+19.76%+24.61%
Shares
-0.70%-3.04%-4.89%-3.69%

Per-share growth (CAGR, ttm) · 10Y

EPS
+26.03%+28.26%+30.13%+65.09%
Sales/share
+21.22%+20.45%+27.24%+26.39%
FCF/share
-0.66%+24.68%+25.92%+29.51%
Book value/share
+100.70%+10.86%-3.50%+3.38%
Price
+11.50%+33.57%+23.49%+33.66%
Total return
+11.50%+33.57%+23.49%+33.66%

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)
36.2×
P/OI (ttm)
30.1×
Fwd P/E
32.9×
P/S (ttm)
6.4×
P/B (mrq)
31.2×
P/FCF (ttm)
27.4×
EV/EBITDA (fy)
28.0×
EV/Sales (ttm)
6.2×
FCF yield (ttm)
3.65%
Buyback yield (realized, 1y)
0.70%
Shareholder yield (realized, 1y)
0.70%
Buyback yield (cash, ttm)
1.61%
Shareholder yield (cash, ttm)
1.61%

Vs own 10Y history

P/E
65th
P/OI
77th
P/S
91st
P/B
91st
P/FCF
95th

Bar = where today’s multiple sits in MEDP’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-17#

Data provided bySource: Twelve Data
1D
+0.75%
5D
-1.72%
1M
+5.60%
3M
+9.37%
YTD
+16.28%
1Y
+11.49%
5Y
+187.19%
1D
+0.75%
5D
-1.72%
1M
+5.60%
3M
+9.37%
YTD
+16.28%
1Y
+11.49%
5Y
+187.19%

Fundamentals#

Revenue

5Y CAGR +22.3%10Y CAGR +21.6%YoY +8.5%
$2.8B TTM$716M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y CAGR +26.2%10Y CAGR +38.5%YoY +16.7%
$607.1M TTM$165.5M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y CAGR +31.8%10Y n/mYoY +25.4%
$18.03 TTM$4.84 Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y CAGR +24.6%10Y CAGR +24.0%YoY −16.6%
$667.6M TTM$196.4M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

TTM: operating cash flow $723M, capex −$55.4M

Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Q3 2026: operating cash flow $216.6M, capex −$20.2M

Shares (diluted)

5Y −21.7%10Y −5.8%YoY −1.5%
28.7M TTM28.4M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y CAGR +25.4%10Y n/mYoY +23.7%
$517.8M TTM$137.5M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Full MEDP financials →

Medpace Holdings, Inc. is a global clinical research organization that provides outsourced clinical development services for biotechnology, pharmaceutical, and medical device companies. Medpace supports the full clinical trial lifecycle, from Phase I through Phase IV, with services that include study design, project management, clinical monitoring, regulatory affairs, data management, biostatistics, medical writing, pharmacovigilance, and post-marketing support. The company also offers specialized laboratory and trial support capabilities such as central laboratory services, bioanalytical testing, imaging core laboratory services, and cardiac safety assessments. Medpace serves clients across North America, Europe, Asia, South America, Africa, and Australia, playing a central role in helping sponsors run complex clinical programs and advance medical products through development.

Cincinnati, OH·6,600 employees·Diagnostics & Research·medpace.com·As of Oct 28, 2026

Recent filings#

All filings and insider trades →

ETFs holding MEDP#

22 of the 193 ETFs ChartRow carries live hold MEDP. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).

FundNameFiled weight
IBBiShares Biotechnology ETF1.0%
VBKVanguard Small-Cap Growth ETF0.3%
IWPiShares Russell Mid-Cap Growth ETF0.3%
IJHiShares Core S&P Mid-Cap ETF0.3%
MDYSPDR S&P MidCap 400 ETF Trust0.3%
VHTVanguard Health Care ETF0.2%
VBVanguard Small-Cap ETF0.1%
VXFVanguard Extended Market ETF0.1%
TickerName1M1D
LLYEli Lilly and Company+12.61%-1.13%
JNJJohnson & Johnson+9.05%-1.36%
ABBVAbbVie Inc.+2.59%-0.59%
MRKMerck & Co. Inc.-1.77%-0.75%
UNHUnitedHealth Group Incorporated Common Stock (DE)-2.93%-5.42%
NVSNovartis AG+5.65%-0.67%
TMOThermo Fisher Scientific Inc.-0.47%-0.66%
AMGNAmgen Inc.+5.88%-0.95%